secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2024-06-26T23:59:59+00:00
Accession:  0001193125-24-169191
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Taysha Gene Therapies prices $75M public offering of common stock and pre-funded warrants
--------------------------------------------------------------------------------

- Gross proceeds ~$75M; 14,361,113 shares at $2.25 each and 18,972,221 pre-funded warrants at $2.249 each.
- Net proceeds ~$70M (~$80.6M if underwriters exercise option for 5M additional shares).
- Cash runway extended into Q4 2026; proceeds fund operating expenses and capex.
- Pre-funded warrants exercisable at $0.001 per share with 4.99%/9.99% ownership caps.
- Jefferies, Goldman Sachs, and Cantor act as book-running managers; closing expected June 27, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312524169191/0001193125-24-169191-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312524169191/d857341d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-169191

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer